CIK 0001664710
- Non-accelerated filer
- Smaller reporting company
Keros Therapeutics, Inc.
Sign in to watch- Ticker
- KROS
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Entity type
- Operating
- EIN
- 811173868
- Phone
- +1 617-314-6297
- Business address
- 1050 WALTHAM STREET, SUITE 302, LEXINGTON, MA, 02421
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $5,619
- in 1 filing, $6K under 10b5-1 plans
Net −$5,619. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2021-02-11 | Lachey Jennifer Chief Scientific Officer | Sale | −1,460 | $63.74 | $93K | 31,384 |
| 2021-02-11 | Lachey Jennifer Chief Scientific Officer | Sale | −1,272 | $64.93 | $83K | 30,112 |
| 2021-02-11 | Lachey Jennifer Chief Scientific Officer | Sale | −1,845 | $65.99 | $122K | 28,267 |
| 2021-02-11 | Lachey Jennifer Chief Scientific Officer | Sale | −262 | $67.05 | $18K | 28,005 |
| 2021-02-11 | Lachey Jennifer Chief Scientific Officer | Sale | −14 | $68.05 | $953 | 27,991 |
| 2021-02-11 | Lachey Jennifer Chief Scientific Officer | Exercise or conversion · Employee Stock Option (right to buy) | −5,300 | 145,605 | ||
| 2021-01-10 | Regnante Keith Chief Financial Officer | Grant or award · Employee Stock Option (right to buy) | +49,150 | 49,150 | ||
| 2021-01-10 | Ordonez Claudia Chief Medical Officer | Grant or award · Employee Stock Option (right to buy) | +42,250 | 42,250 | ||
| 2021-01-10 | Lachey Jennifer Chief Scientific Officer | Grant or award · Employee Stock Option (right to buy) | +42,250 | 42,250 | ||
| 2021-01-10 | Seehra Jasbir Chief Executive Officer | Grant or award · Employee Stock Option (right to buy) | +127,200 | 127,200 | ||
| 2020-12-17 | GRAY MARY ANN Director | Grant or award · Stock Option (right to buy) | +16,587 | 16,587 | ||
| 2020-11-17 | Nussbaum Ran Director | Purchase | +26,634 | $50.00 | $1.3M | 2,288,151 |
| 2020-11-17 | Nussbaum Ran Director | Purchase | +12,966 | $50.00 | $648K | 1,122,768 |
| 2020-11-17 | Nussbaum Ran Director | Purchase | +14,400 | $50.00 | $720K | 1,228,326 |
| 2020-11-17 | Nussbaum Ran Director | Purchase | +6,000 | $50.00 | $300K | 155,262 |
| 2020-11-17 | Kariv Tomer Director | Purchase | +26,634 | $50.00 | $1.3M | 2,288,151 |
| 2020-11-17 | Kariv Tomer Director | Purchase | +12,966 | $50.00 | $648K | 1,122,768 |
| 2020-11-17 | Kariv Tomer Director | Purchase | +14,400 | $50.00 | $720K | 1,228,326 |
| 2020-11-17 | Kariv Tomer Director | Purchase | +6,000 | $50.00 | $300K | 155,262 |
| 2020-11-17 | Pontifax Management 4 G.P. (2015) Ltd. 10% owner | Purchase | +26,634 | $50.00 | $1.3M | 2,288,151 |
Page 29 of 36 · 707 trades